Minoxidil: effectiveness and prospects for use in the treatment of androgenetic alopecia

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Androgenetic alopecia (AGA) is the most common hair loss condition affecting both men and women. The most common drug of choice in the treatment of AGA is minoxidil, which has vasodilating, anti-inflammatory and antiandrogenic properties; it is an inducer of the Wnt/β-catenin signaling pathway, and enhances the synthesis of growth factors. Minoxidil affects several pathogenesis of AGA at once, prolonging the anagen phase and reducing the telogen phase, enhancing DNA synthesis and stimulating proliferative processes. Currently, minoxidil is considered as a drug for both local and systemic therapy of AGA. Treatment methods with minoxidil in combination with finasteride, spironolactone, topical tretinoin, as well as platelet-rich plasma, low-intensity laser therapy and microneedling are of particular, which significantly expands the treatment options for patients with AGA.

Толық мәтін

Рұқсат жабық

Авторлар туралы

E. Shatokhina

Central State Medical Academy of the Administrative Department of the President of the Russian Federation; Medical Research and Educational Center, Lomonosov Moscow State University

Хат алмасуға жауапты Автор.
Email: e.a.shatokhina@gmail.com
ORCID iD: 0000-0002-0238-6563

Dr. Sci. (Med.), Professor at the Department of Dermatovenereology and Cosmetology, Leading Researcher at the Department of Internal Medicine

Ресей, Moscow; Moscow

O. Klyushina

Central State Medical Academy of the Administrative Department of the President of the Russian Federation

Email: pharmateca@yandex.ru
ORCID iD: 0009-0002-8508-6300
Ресей, Moscow

S. Mayransaeva

Central State Medical Academy of the Administrative Department of the President of the Russian Federation

Email: pharmateca@yandex.ru
ORCID iD: 0009-0000-8395-734X
Ресей, Moscow

Әдебиет тізімі

  1. Devjani S., Ezemma O., Kelley K.J., et al. Androgenetic Alopecia: Therapy Update. Drugs. 2023;83(8):701–15. doi: 10.1007/s40265-023-01880-x.
  2. Piraccini B.M., Alessandrini A. Androgenetic alopecia. J Ital Dermatol Venereol. 2014;149(1):15–24.
  3. Lolli F., Pallotti F., Rossi A., et al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9–17.
  4. Mysore V., Parthasaradhi A., Kharkar R.D., et al. Expert consensus on the management of androgenetic alopecia in India. Int. J. Trichol. 2019;11(3):101–6.
  5. Wambier C.G., Mehta N., Goren A., Cadegiani F.A. COVID-19, androgens, and androgenic alopecia. Dermatol Rev. 2020;2(3):146–53.
  6. Lee J., Yousaf A., Fang W., Kolodney M.S. Male balding is a major risk factor for severe COVID-19. J Am Acad Dermatol. 2020;83(5):e353–4.
  7. Wambier C.G., Vaсo-Galvбn S., McCoy J., et al. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: the “Gabrin sign”. J Am Acad Dermatol. 2020;83(2):680–82.
  8. Wambier C.G., Vaсo-Galvбn S., McCoy J., et al. Androgenetic alopecia in COVID-19: compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. J Am Acad Dermatol. 2020;83(6):e453–54.
  9. Ho C.H., Sood T., Zito P.M. Androgenetic alopecia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
  10. Kranz D. Young men’s coping with androgenetic alopecia: acceptance counts when hair gets thinner. Body Image. 2011;8(4):343–48.
  11. Cash T.F. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992;26(6):926–31.
  12. Davis D.S., Callender V.D. Review of quality of life studies in women with alopecia. Int J Womens Dermatol. 2018;4(1):18–22.
  13. Nestor M.S., Ablon G., Gade A., et al. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759–81. doi: 10.1111/jocd.14537.
  14. Российское общество дерматовенерологов и косметологов. Клинические рекомендации по диагностике и лечению Андрогенной алопеции. 2022. [Russian Society of Dermatovenerologists and Cosmetologists. Clinical guidelines for the diagnosis and treatment of Androgenetic alopecia. 2022. (In Russ.)].
  15. Hosking A.M., Juhasz M., Atanaskova Mesinkovska N. Complementary and Alternative Treatments for Alopecia: A Comprehensive Review. Skin Appendage Disord. 2019;5(2):72–89. doi: 10.1159/000492035.
  16. Gupta A.K., Talukder M., Venkataraman M., Bamimore M.A. Minoxidil: a comprehensive review, J Dermatol Treatm. 2021. doi: 10.1080/09546634.2021.1945527.
  17. Kanti V., Messenger A., Dobos G., et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version. J Eur Acad Dermatol Venereol. 2017;32(1):11–22. doi: 10.1111/jdv.14624.
  18. Zins G.R. The history of the development of minoxidil. Clin Dermatol. 1988;6(4):132–47. doi: 10.1016/0738-081x(88)90078-8.
  19. Олисова О.Ю., Гостроверхова И.П. Миноксидил в практике врача-трихолога Медицинский совет. 2018;6:145–47. [Olisova O.Yu., Gostroverkhova I.P. Minoxidil in trichological practice. Meditsinskiy sovet = Medical Council. 2018;(6):145–147. (In Russ.)].doi: 10.21518/2079-701X-2018-6-145-147.
  20. Shorter K., Farjo N.P., Picksley S.M., et al. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008;22(6):1725–36.
  21. Chen X., Liu B., Li Y., et al. Dihydrotestosterone Regulates Hair Growth Through the Wnt/β-Catenin Pathway in C57BL/6 Mice and In Vitro Organ Culture. Front Pharmacol. 2020;10:1528. doi: 10.3389/fphar.2019.01528.
  22. Гостроверхова И.П. Комбинированная терапия очаговой алопеции. Дисс. канд. мед. наук. М., 2011. [Gostroverkhova I.P. Combination therapy of focal alopecia. Diss. Cand. of Med. Sciences. Moscow, 2011. (In Russ.)].
  23. Олисова О.Ю., Кочергин Н.Г., Вертиева Е.Ю. Андрогенная алопеция: патогенетические механизмы и подходы к лечению. Российский журнал кожных и венерических болезней. 2013;3:53–8. [Olisova O.Yu., Kochergin N.G., Vertieva E.Yu. Androgenetic alopecia: pathogenetic mechanisms and approaches to treatment. Rus J Skin Venereal Dis. 2013;3:53–58. (In Russ.)]. doi: 10.17816/dv36808.
  24. Pekmezci E., Turkoglu M. Minoxidil acts as an antiandrogen: a study of 5a-reductase zype 2 gene expression in a human keratinocyte cell line. Acta Dermatovenerol Croatica. 2017;25(4):271.
  25. Pekmezci E., Turkoglu M., Gokalp H., et al. Minoxidil downregulates interleukin-1 alpha gene expression in HaCaT cells. Int J Trichol. 2018;10(3):108–12.
  26. Buhl A.E., Waldon D.J., Baker C.A., Johnson G.A. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J Invest Dermatol. 1990;95(5):553–77.
  27. Goren A., Castano J.A., McCoy J., et al. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatol Ther. 2014;27(3):171–73.
  28. Goren A., Sharma A., Dhurat R., et al. Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. Dermatol Ther. 2018;31(6):e12741.
  29. Ramos P.M., Goren A., Sinclair R., et al. Oral minoxidil bioactivation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss. J Eur Acad Dermatol Venereol. 2020; 34(1):e40–1.
  30. Sinclair R.D. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104–9.
  31. Randolph M., Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J. Am. Acad. Dermatol. 2020;84(3):737–46.
  32. Ramos P.M., Sinclair R.D., Kasprzak M., et al. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial. J Am Acad Dermatol. 2020;82(1):252–53.
  33. Panchaprateep R., Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global photographic assessment. Dermatol Ther. 2020; 10(6):1345–57.
  34. Jimenez-Cauhe J., Saceda-Corralo D., Rodrigues-Barata R., et al. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol. 2019;81(2):648–49.
  35. Vaсу-Galvбn S., Pirmez R., Hermosa-Gelbard A., et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644–51.
  36. Product monograph; hair regrowth treatment, minoxidil topical solution USP, 20 mg/ml (2% w/v) [cited 2021 May 30].
  37. Pfizer Loniten (Minoxidil) Tablet, 2.5 mg & 10 mg, for oral use [Internet]. 2013. [cited 2021 Apr 26].
  38. Rogers N.E., Avram M.R. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59(4):547–66.
  39. Sinclair R., Trindade de Carvalho L., Ferial Ismail F., et al.Treatment of male and female pattern hair loss with sublingual minoxidil: a retrospective case-series of 64 patients. J Eur Acad Dermatol Venereol. 2020;34(12):e795–96.
  40. Hu R., Xu F., Sheng Y., et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients. Dermatol. Ther. 2015;28(5):303–8.
  41. Tanaka Y., Aso T., Ono .J, et al. Androgenetic alopecia treatment in Asian men. J Clin Aesthet Dermatol. 2018;11(7):32–5.
  42. Rafi A.W., Katz R.M. Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA. ISRN Dermatol. 2011;2011:241953.
  43. Suchonwanit P., Srisuwanwattana P., Chalermroj N., et al. A randomized, double blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol. 2018;32(12):2257–63.
  44. Abdel-Raouf H., Aly U.F., Medhat W., et al. A novel topical +combination of minoxidil and spironolactone for androgenetic alopecia: clinical, histopathological and physicochemical study. Dermatol Ther. 2021;34(1):e14678.
  45. Bazzano G.S., Terezakis N., Galen W. Topical tretinoin for hair growth promotion. J Am Acad Dermatol. 1986;15(4 Pt. 2):880–93.
  46. Sharma A., Goren A., Dhurat R., et al. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatol Ther. 2019;32(3):e12915.
  47. Alves R., Grimalt R. Platelet-rich plasma in combination with 5% minoxidil topical solution and 1 mg oral finasteride for the treatment of androgenetic alopecia: a randomized placebo-controlled, double-blind, half-head study. Dermatol Surg. 2018;44(1):126–30.
  48. Zhou Y., Chen C., Qu Q., et al. The effectiveness of combination therapies for androgenetic alopecia: a systematic review and meta-analysis. Dermatol Ther. 2020;33(4):e13741.
  49. Kim Y.S., Jeong K.H., Kim J.E., et al. Repeated microneedle stimulation induces enhanced hair growth in a murine model. Ann Dermatol. 2016;28(5):586–92.
  50. Sharma A., Surve R., Dhurat R., et al. Microneedling improves minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. J Biol Regul Homeost Agents. 2020;34(2):659–61.
  51. Shah K.B., Shah A.N., Solanki R.B., et al. A comparative study of microneedling with platelet-rich plasma plus topical minoxidil (5%) and topical minoxidil (5%) alone in androgenetic alopecia. Int J Trichol. 2017;9(1):14.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Рис. 1. Доступные методы лечения АГА (адаптировано с изменениями из A.K. Gupta et. al.) [16]

Жүктеу (195KB)
Метадеректер
3. Рис. 3. Чувствительность к терапии миноксидилом в зависимости от уровня фермента сульфотрансферазы (адаптировано из A.K. Gupta et. al.) [16]

Жүктеу (82KB)
Метадеректер

© Bionika Media, 2023

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>